Should deep-sequenced amplicons become the new gold-standard for analysing malaria drug clinical trials? by Jones, Sam et al.
1 
 
Should deep-sequenced amplicons become the new gold-1 
standard for analysing malaria drug clinical trials? 2 
 3 
Running Title: Amplicon analysis of malaria drug trials 4 
 5 
Sam Jones1, Katherine Kay2, Eva Maria Hodel3, Maria Gruenberg4, Anita Lerch4,5, Ingrid Felger4, Ian 6 
Hastings1* 7 
 8 
1 Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, 9 
United Kingdom. 10 
2 Metrum Research Group, Tariffville, Connecticut, United States of America. 11 
3 Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L69 7BE, 12 
United Kingdom. 13 
4 Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, 4002, 14 
Switzerland. 15 
5 Current address: Eck Institute for Global Health Department of Biological Sciences University of , , 16 
Notre Dame Notre Dame, IN 46556 United States of America, ,  17 
 18 
*corresponding author: ian.hastings@lstmed.ac.uk  19 
AAC Accepted Manuscript Posted Online 12 July 2021
Antimicrob Agents Chemother doi:10.1128/AAC.00437-21
Copyright © 2021 Jones et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.







 Journals- on [14/07/2021]. R
e-use and distribution is strictly not perm







Conflict of interest statement: None of the authors have any associations that might pose a 22 
conflict of interest with authorship of this manuscript. 23 
 24 
Funding: This work was supported by the UK Medical Research Council (grant numbers G1100522 25 
and MR/ L022508/1); the Bill and Melinda Gates Foundation (grant number1032350); 26 
and the Malaria Modeling Consortium (grant number UWSC9757). Swiss National Science 27 




Keywords: Malaria, , drug trials, drug resistance, TES, molecular correction, PCR P. falciparum32 
correction.  33 







 Journals- on [14/07/2021]. R
e-use and distribution is strictly not perm







Background. Regulatory clinical trials are required to ensure the continued supply and deployment 36 
of effective antimalarial drugs. Patient follow-up in such trials typically lasts several weeks as the 37 
drugs have long half-lives and new infections often occur during t38 
is therefore used to distinguish drug failures from new infections. The current WHO-recommend 39 
method for molecular correction uses length-polymorphic alleles at highly diverse loci but is 40 
inherently poor at detecting low density clones in polyclonal infections. This likely leads to 41 
substantial underestimates of failure rates, delaying the replacement of failing drugs with potentially 42 
lethal consequences. Deep sequenced amplicons (AmpSeq) substantially increase the detectability of 43 
low-  44 
Methods. Pharmacological simulation of clinical trials was used to evaluate the suitability of AmpSeq   45 
for molecular correction. We investigated the impact of factors such as the number of amplicon loci 46 
47 
the local epidemiology of malaria transmission, and the potential impact of genetic signals from 48 
gametocytes. 49 
Results. AmpSeq greatly improved molecular correction and provided accurate drug failure rate 50 
estimates. The use of 3 to 5 amplicons was sufficient, and simple, non-statistical, criteria could be 51 
used to classify recurrent infections as drug failures or new infections. 52 
Conclusions. These results suggest AmpSeq is strongly placed to become the new standard for 53 
molecular correction in regulatory trials, with its potential extension into routine surveillance once 54 
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Clinical trials and Therapeutic efficacy studies (TES) of anti-malarial drugs are key components of 59 
public health provision in malaria endemic countries. The role of clinical trials is to ensure a steady 60 
supply of effective drugs, while the role of TES is to provide on-going surveillance on the efficacy of 61 
local front-line drugs, and enable rapid replacement of failing drugs to avoid the increased morbidity 62 
and mortality associated with drug resistance (1)  . 63 
 64 
In principle clinical trials and TES are simple: patients are treated with the drug being evaluated, and 65 
the number of patients with drug failures are counted to provide estimates of drug effectiveness.  In 66 
practice, this is challenging because most current malaria drugs have long half-lives such that drug 67 
failures are suppressed and may only become patent several weeks after treatment. Ongoing 68 
malaria transmission means that patients often acquire new infections during the long follow-up 69 
period so a key methodological requirement of clinical trials and TES is to correctly classify patients 70 
returning with detectable malaria parasites during follow-71 
72 
classification is achieved using molecular correction protocols which rely on genotyping malaria 73 
parasites in the blood of the infected patient at the time of  drug treatment and if that patient 74 
returns with a recurrence at any time during  the 4-6 week follow-up period (2)75 
between treatment and follow- - 76 
indicate a new infection. Deciding whether or not the samples match is highly problematic, and the 77 
number of shared alleles required to define a match (and hence a drug failure) depends on the 78 
methodology used - .   The World Health Organization (WHO) recommends three markers (2) i.e. (3 5)79 
merozoite surface protein-1 ( ), merozoite surface protein-2 ( ) and glutamate rich protein msp-1 msp-280 
( ) though alternative markers are available such as the microsatellite markers used by the glurp81 
Centers for Disease Control and Prevention (6). The three WHO markers and the CDC microsatellite 82 
markers all rely on identifying alleles by their lengths (in contrast to amplicons, discussed later, 83 
where allele differ in their sequence). Length-polymorphic genotyping uses PCR amplification of 84 
molecular markers in patient blood samples, followed by fragment sizing of the PCR products using 85 
agarose gels or capillary electrophoresis.  Malaria infections often contain multiple parasite clones 86 
both at treatment (when the multiplicity of infection, MOI, is typically 3 to 8 malaria clones per 87 
person in high transmission areas) and at recurrence (where patients may present with a mixture of 88 
recrudescence clones and new infections). There is substantial variation is the density of individual 89 
clones in these multi-clonal infections and existing methods based on length polymorphism are 90 
notoriously poor at detecting low-density clones. These methods typically regard genetic signals less 91 
92 
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20% to 30% that of the dominant clone are not identified. There have been recent calls for a review 93 
of the WHO-recommended methodology, (5, 7) following scientific discussion of misclassification 94 
with length-polymorphic ( (3, 7-  and microsatellite (4, 10) approaches.  msp-1, msp-2, glurp) 9)95 
Deep sequencing of highly SNP-polymorphic amplicons (AmpSeq) is an attractive next-generation 96 
methodology, experimentally shown to have much greater ability to detect low-density clones than 97 
existing methods based on length-polymorphic genotyping. This has the potential to substantially 98 
improve molecular correction over existing methods. AmpSeq methods are well established in the 99 
wider malarial context for tracking specific genes (e.g., for drug resistance) within populations (11-100 
13), and for evaluating the efficacy of the RTS,S/AS01 vaccine (14). AmpSeq as a method to genotype 101 
malaria parasites in clinical trials is relatively novel (15) and, despite its putative advantages, has not 102 
yet been used as the primary genotyping endpoint for a clinical trial or TES (although it has been 103 
used to re-analyze archived blood samples (15)). This paper uses an  pharmacological in silico104 
approach to evaluate the putative advantages AmpSeq for improving molecular correction. This 105 
builds on our previous work using mechanistic pharmacokinetic/pharmacodynamic (mPK/PD) 106 
107 
failure rate in the simulation is known. This allowed a critical appraisal of existing TES methodology 108 
(3, 4, 16) and enabled us to quantify the accuracy of molecular correction based on length-109 
polymorphic and microsatellite markers. A reasonable hypothesis is that the more accurate and 110 
sensitive genotyping afforded by AmpSeq will lead to more accurate efficacy estimates in clinical 111 
trials and TES than existing, widely used methods mandated by the WHO and CDC. Here, we apply 112 
this mPK/PD modelling approach to quantify the accuracy of efficacy estimates produced using 113 
published AmpSeq data of 5 SNP-polymorphic markers/loci (Gruenberg et al. 2019). Our aim is to 114 
identify any potential problems and pitfalls  before they occur , optimise the likely use in silico in vivo115 
of AmpSeq for molecular correction in regulatory trials, and suggest appropriate guidelines for their 116 
deployment.  117 
 118 
The main advantage of AmpSeq over existing methods is its increased sensitivity i.e. increased ability 119 
to detect genetic signals from malaria clones present at low densities in human blood samples. 120 
Sequencing may achieve substantial read depths but a practical problem in processing these reads is 121 
to distinguish low-number reads from artefacts. This requires a bioinformatics cut-off (BIC) value, 122 
below which low- er reads are regarded as artefacts and ignored. In the case of malaria it numb123 
appears that BIC=1% is the most robust value, as extensively discussed elsewhere (17) although we 124 
also investigate a (hypothetical, perfect) BIC-> 0% and an alternative BIC of 2%. In all cases BIC 125 
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should be read as the sensitivity of the method to detect low-density malaria clones e.g. with 126 
BIC=1% then any malaria clone(s) whose number/density is less than 1% of the total parasitaemia in 127 
a human will remain undetected. 128 
 129 
Summary of m hodology  et130 
Simulating parasitaemia and their genotypes in therapeutic efficacy trials 131 
Published mPK/PD methodologies (3, 4) were used to generate datasets of parasite numbers over 132 
time post-treatment for 5,000 simulated adult patients treated with either hydroartemisinin-Di133 
Piperaquine (DHA-PPQ) or Artemether-Lumefantrine (AR-LF) These simulated patients differed in . 134 
key factors related to their parasite dynamics post-treatment i.e. their individually-assigned PK 135 
parameters, the level of resistance in the pat136 
treatment, the local intensity of transmission and so on, as discussed later. Note that mPK/PD 137 
methodology tracks number, rather than density, of parasites; see Supplementary Material, Part 1 138 
for how to interconvert these metrics. The simulations produce parasitae a post-treatment for mi139 
each patient simulated in the trial. Specifically, we track individual parasite clones present at 140 
treatment (which may be cleared or recrudesce) and of new infections.   141 
 142 
These simulated patients were followed up for 42 days following DHA-PPQ treatment or 28 days 143 
following AR-144 
scheduled days of follow-up i.e. days 3, 7 and every week thereafter in line with WHO guidelines 145 
(18). For each patient, our model calculated the day of follow-up when recurrent parasites were first 146 
detectable according to the procedure described in (3), noting that some patients will never show   147 
recurrence for one of the two reasons i.e. (i) the drug cleared the original infection and the patient 148 
never acquired a patent new infection during follow-up, or (ii) the drug did not clear the original 149 
infection but follow-up ended before the recrudesce became patent. 150 
 151 
Genetic diversity of infections at treatment is termed the Multiplicity of Infection (MOI) which is the 152 
number of (detectable) genetically distinct parasite clones in the blood sample. MOI depends on 153 
intensity of transmission so  s were explored Eac parasite clone within the   . h 154 
MOI had a total number of parasites drawn from a log-uniform distribution according to two ranges: 155 
1010 to 1011 (the default range) and 108 to 1011 (for sensitivity analysis). Genetic diversity in 156 
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recurrences depends on the Force of Infection (FOI) which is the rate at which new infections 157 
become established in a patient. We incorporated FOI as the mean of a Poisson distribution from 158 
which the day(s) of new infections are randomly selected for each patient. The FOI means were 0, 2, 159 
8 and 16 per year, broadly representing areas with no, low, medium and high ongoing transmission, 160 
respectively. New infections emerge from the liver as cohorts of 105 total parasites and their fate 161 
(cleared or survive) depends on drug concentrations in that host on the days following their 162 
emergence from the liver (many emergences that appear shortly after treatment will be killed by the 163 
highly persistent partner drugs PPQ or LF). Each malaria clone at treatment or recurrence had 164 
genotypes defined at five AmpSeq markers (  and ) with allelic cpmp, ama1-D3, cpp, csp msp-7165 
diversity obtained from (15). We use the first three markers by default but also included the less 166 
diverse markers  and   in our simulations as these may be used when other markers fail to csp msp-7167 
amplify (15) and allows us to evaluate whether increasing the number of  markers would Ampseq168 
significantly improve accuracy. 169 
 170 
A technical description of this methodology, including mPK/PD parameters and references to 171 
previous work is provided in the Supplementary Material, part 1. All simulations were conducted 172 
using the programming language R (version 1.2.5001) (19). The simulated data from the trial was 173 
then processed as follows. 174 
 175 
Allele detection in simulated datasets:  the blood sampling limit and bioinformatics cut-off (BIC) 176 
Our model determined which AmpSeq alleles were detected in initial and recurrent samples with a 177 
modified version of the methodology described in (3, 4) and described in the Supplementary 178 
Material, part1. It follows a two-stage process as follows: 179 
1. A clone must have a sufficiently high parasitaemia that infected erythrocytes  physically 180 
enter a finger-prick blood sample; this is obviously a prerequisite (but not a guarantee)  for 181 
182 
(3, 4) and two limits were utilized: 108 total parasites as used previously (3), and 107 183 
total parasites. 184 
2.  amplicon allele will only be identified by the bio-informatics pipeline as present in the An 185 
blood sample if it exceeds an empirically-determined threshold number and/or proportion  186 
187 
threshold the bioinformatic cut-off (BIC) inherent in the experimental protocol. In our 188 
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previous work [15]189 
[15]; consequently we use this value (i.e. BIC=1%) as the baseline for our simulations We . 190 
also investigated a more stringent threshold of 2% (i.e. BIC=2%). Since BIC is experimentally 191 
determined, we must anticipate settings where, for example, researchers are sufficiently 192 
confident in their technology and results  at they regard reads present at proportions th193 
above one in 5 of the total reads, or even above 1 in 1000 (i.e. BIC=0.02% or BIC=0.1% 00 194 
respectively) as confirming  the presence of that AmpSeq allele. Also, future technical 195 
advances may allow researchers to reduce this threshold even further e.g. to BIC=0.001. 196 
Rather than investigate all these BIC thresholds separately (e.g. BIC=0.2%, 0.1%, 0.001%, etc) 197 
we take the approach of investigating how the results would change as the threshold 198 
->0). The logic is 199 
that if there is little improvement in accuracy as BIC falls from BIC=1% to BIC->0, then other 200 
values (such as the exemplar values BIC=0.2%, 0.1%, 0.001%) would also have little impact. 201 
 202 
Matching threshold for molecular correction and subsequent estimation of failure rate  203 
Classification of recurrences as drug failures (i.e. recrudescences) or new infections was primarily 204 
based on the three most diverse markers and   cpmp, cpp ama1-D3.  to205 
classify a recurrence as a recrudescence when the number of markers with at least one shared allele 206 
between the initial and recurrent samples were greater than or equal to the matching threshold. For 207 
208 
markers to classify the recurrence as recrudescence. Recurrences below this threshold were 209 
classified as new infections. Once all recurrences are classified as recrudescences or new infections, 210 
the drug failure rate estimates in the trial were calculated using survival analysis, as per WHO 211 
procedure (18). 212 
 213 
The potential impact of gametocyte genotyping signals. 214 
Mature falciparum infections often contain relatively high densities (up to 10% of total parasitaemia) 215 
of their transmission stage, gametocytes. These stages do not cause symptoms, are unaffected by 216 
most drugs, and decline slowly post-treatment with a half-life of around 2 to 6 days.  This slow 217 
decline has raised concerns that their genetic signals could be detected when genotyping 218 
recurrences using highly sensitive genotyping techniques such as AmpSeq. These signals would be 219 
mistaken for signals arising from persisting asexual stages, would be counted in the matching 220 







 Journals- on [14/07/2021]. R
e-use and distribution is strictly not perm





threshold described above, and hence bias molecular correction by increasing the likelihood of a 221 
222 
recrudescences.  Assuming we know the number of gametocytes at treatment, the lag time before 223 
they start to decline, and the rate of decline thereafter, it is straightforward to track their numbers 224 
follow treatment and hence their potential detection and impact on molecular correction. ing 225 
However, discussions of calibration, algebra, and presentation of results became rather lengthy so, 226 
to maintain focus in the main text, we describe how we simulate their likely impact in a stand-alone  227 
Supplementary Material, Part 3.   228 
We provide a summary of the parameters used in the simulations, and their values, in Table 1.  229 
 230 
Results. 231 
Failure rate estimates for simulated populations with varied MOI and FOI treated with DHA-PPQ or 232 
AR-LF are shown in Figure 1. Three important model parameters were used as baseline scenario: 233 
8 total parasites, and initial parasite number drawn from a log-234 
uniform distribution between 1010 and 1011. The true failure rate for DHA-PPQ was 11.6% and 6.3% 235 
in areas of high and low MOI respectively. True failure rates increase with MOI as the drug has to 236 
successfully clear more clones present at time of treatment; this is discussed in more detail 237 
elsewhere (16) but note that the fates of the clones are not independent because they share the 238 
239 
the failure rate for MOI=1). The corresponding true failure rates for AR-LF were 12.2% and 8.2% . 240 
Failure rate depends on MOI for the reasons given above. However, it does depend on FOI 241 
because FOI only determines the re-infection rate. We count a drug failure as anyone whose 242 
treatment fails to clear all the parasites present at treatment irrespective of whether or not the 243 
recrudescence is masked by a new infection. 244 
245 
produced highly accurate failure rate estimates when analysing 3 loci (Figure 1A or using thresholds ) 246 
when analysing five loci (Figure 1B). Molecular correction using Ampseq therefore 247 
performed much better than previously observed in our analysis of similar matching thresholds 248 
based on length-polymorphic WHO-recommended markers, and for microsatellites (3, . This was 4)249 
true under all scenarios i.e. for DHA-PPQ and AR-LF, in both high and low MOI and across all FOI 250 
values (Supplementary Material, Part 2). The accuracy of using three loci implies it is unnecessary to 251 
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genotype more AmpSeq loci and this appears to be the case: genotyping 4 or 5 additional loci did 252 
not improve accuracy (Supplementary Material, Part 2 and Figure 1B  ).253 
An important operational question is whether technological advances capable of reducing BIC to 254 
below 1% will results in better estimates. This is unlikely given the accuracy of using BIC=1% (i.e. 255 
Figure 1) but we re-ran the analyses using the theoretical minimum value of BIC->0% and, as 256 
expected, found no improvement. Notably, increasing BIC to 2% also had a negligible impact on 257 
accuracy (Supplementary Material, Part2). 258 
Sensitivity analyses were conducted by repeating simulations with altered model parameters  to259 
confirm eir values did not affect the conclusions. Lower blood sampling limit or increasing initial th260 
parasite distributions showed no qualitative differences and negligible quantitative differences to 261 
results shown on Figure 1 (Supplementary Material, Part 2).   262 
 263 
Discussion. 264 
Existing research has identified suitable SNP-polymorphic AmpSeq loci for genotyping malaria 265 
parasites (14, 17) and confirmed and quantified their superior ability to detect low-density clones 266 
compared to traditional length-polymorphic genotyping methods (15, 17, 20). AmpSeq also provided 267 
improved estimates of MOI (21) and identified appropriate thresholds for allele detection (17, 22). 268 
Here, we aimed to quantify the hypothesized increase in the accuracy of failure rate estimates in 269 
270 
density clones.   271 
 272 
Figure 1 (and Fig S2.5 which shows analogous results for 4 loci), suggests an important diagnostic in 273 
the use of AmpSeq which serves to (a) check that molecular correction is based on a sufficient 274 
number of AmpSeq loci, and (b) to identify an appropriate choice of matching threshold that enable 275 
AmpSeq markers to solidly distinguish recrudescences from new infections.  At the lowest threshold 276 
of 1, unrelated parasite clones of the sample pair (i.e. treatment and recurrence) may match purely 277 
by chance (often due  to a dominant allele), meaning that a new infection would be  mistakenly 278 
classified as recrudescence (8). As the threshold increases, this probability of matching- -chance by279 
declines to negligible levels, and failure estimates become stable with respect to threshold. 280 
Providing this pattern of rapid fall to a plateau occurs, the choice of matching threshold can be any 281 
Our plots suggest we could use matches at 2 or 3 loci when 282 
using 3 Ampseq markers (Figure 1A), 3 or 4 matches when using four markers (Figure S2.5), and 3, 4 283 
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or 5 when using 5 markers (figure 1B). Note that the appropriate choice of threshold depends on the 284 
study site because the probability of matching by chance increases if the AmpSeq markers are less 285 
diverse than those simulated here, and/or as transmission intensity (FOI) increases the genetic 286 
complexity of the infections (MOI). Rather than recommending a universal threshold , we a priori287 
recommend that the choice be based on the diagnostic plot generated for each study (i.e. 288 
demonstration that the plot flattens and threshold occurs in the flat portion) so this diagnostic is 289 
likely to become essential to validate the methodology as clinical data starts to accumulate.  It was 290 
notable that adding two less diverse markers to our core three AmpSeq still passed this diagnostic 291 
(Figure 1B) suggesting only a few, well-characterised  AmpSeq loci may be required to achieve 292 
accurate molecular correction. 293 
 294 
This diagnostic is one reason why we regard AmpSeq as a the 295 
Genotyping based on msp1/msp2/glurp fails this diagnostic because the curve continues to fall and 296 
never reaches a plateau. Use of msp1/msp2/glurp appears to provide accurate overall failure rate 297 
estimates provided a recrudescence is defined on a >=2/3 algorithm (3).  However, it is important to 298 
note that classification of individual patients is often incorrect in the >=2/3 algorithm applied to 299 
msp1/msp2/glurp  but the errors balance i.e. the number of recrudescences misclassified as new 300 
infections is roughly equal to  the number of new infections misclassified as recrudescences (Figure 3 301 
of (3)). This is obviously rather unsatisfactory because the balance can be shifted by factors such FOI 302 
and duration of follow-  AmpSeq seems to provide accurate classification of individual patient up. 303 
outcomes which is much preferable to balancing errors and allows more accurate correlations 304 
between treatment outcome and underlying risk factors . allows the presence of drug resistance i.e305 
mutations to be more closely tested against individual treatment success/failure.  Note that this 306 
correlation is usually obtained as an Odds Ratio for presence of a drug resistance marker at 307 
treatment, and patient failure (23). There is currently no way of achieving the logical next step i.e. to 308 
construct the clonal haplotype that contains both the drug marker and its Ampseq markers, so that 309 
the odds ratio of a resistance clone failing treatment could be calculated (although, in principle, this 310 
may be possible if MOI is low and the clones differ substantially in their density such than haplotypes 311 
could be inferred  ).312 
 313 
The results presented here assume alleles can only be detected at frequencies >1% within a sample 314 
(i.e., BIC=1%). In reality, experimental mixtures suggest that AmpSeq is potentially even more 315 
sensitive than this but a BIC=1% is required to avoid inclusion of PCR errors / artefacts and 316 
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environmental contaminations (15 . A value of BIC=1% reflects present technology for robust 317 
genotyping (15) but we wished to anticipate and evaluate technological advances that may reduce 318 
this limit. Our  results show that reducing BIC to the hypothetical perfect detection limit as BIC->0% 319 
(and assuming no false positive occurred)  made negligible difference to the accuracy of the in silico320 
method; this most likely occurs because low-density clones that could be detected by the 321 
hypothetical perfect  BIC->0% are likely to be below the blood sampling limit i.e. are unlikely to 322 
physically enter the finger-prick samples used in clinical trials and routine TES studies. The additional 323 
results (Supplementary Material, Part 2) also showed that BIC could be increased to 2% with 324 
negligible reductions in accuracy of molecular correction. Many surveys have shown a high 325 
prevalence of extremely low-density clones by deep-sequencing venous blood samples whose 326 
volumes are several magnitudes larger than a finger-prick. Whether resistant clones present at such 327 
extreme low-density are likely to recrudesce after treatment is unknown (one argument is that they 328 
are controlled by host immunity so are unlikely to recrudescence). Unfortunately, we cannot 329 
genotype such low density clones and test this directly in field trials using current technology 330 
because, as described above, the sequence depth is not the issue; any amplification step in the 331 
genotyping protocol will limit the sensitivity to around BIC=1% to avoid contamination producing too 332 
many low-density false positive haplotypes calls. Furthermore, setting BIC % reduces the risk of =1333 
detecting genotypes of gametocytes persisting from treatment; the dangers of this have been raised 334 
previously (e.g. (15, 24)) and are quantified in our Supplementary Material, part 3.  335 
 336 
The possibility of detecting gametocyte signals when genotyping blood samples in follow-up is 337 
illustrated on  Figure 2 whose panels should be interpreted as follows: provid  gametocytaemia is ed338 
above the blood sampling limit (i.e. >108 gametocytes in the human host shown by the horizontal 339 
dotted line) at time of recurrence, then each of the four exemplar clones will be: 340 
 Detectable by Ampseq in all recurrences in the boxplots whose parasitaemia lies below the 341 
green line (because gametocytes in that clone are present at >1% of total parasitaemia) 342 
 Detectable by standard length polymorphism (e.g. the standard WHO-recommended 343 
methods based on 2 and ) in all recurrences in the boxplots whose msp1, msp glurp344 
parasitaemias lies below the blue line (because gametocytes in that clone are present at 345 
>25% of total parasitaemia) 346 
 347 
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